SCHEMBL4715216

SCHEMBL4715216

Cc1nc(C#Cc2cccc(F)c2)ccc1C(=O)O

nearest known ligand 0.64

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 12/20 0.51
SLC6A2 P23975 1/20 0.43
HAO1 Q9UJM8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4711712 0.84 TSHR (0.50) GRM5
SCHEMBL4714732 0.80 GRM5 (0.47) GRM5
SCHEMBL4713184 0.78 TACR3 (0.46)
SCHEMBL4710584 0.77 GRM5 (0.52) GRM5SLC6A2
SCHEMBL4577655 0.77 HNF4A (0.54) GRM5HAO1
SCHEMBL4713781 0.76 GRM5 (0.51) GRM5SLC6A2HAO1
SCHEMBL4712862 0.76 TP53 (0.46) GRM5
SCHEMBL4715310 0.74 HSD11B1 (0.56)
SCHEMBL4710830 0.74 GRM5 (0.67) GRM5
SCHEMBL4713917 0.73 GRM5 (0.41) GRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0998459-B1 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2008-04-23 EP disclosed
US-6656957-B1 Marked and selective modulating, especially antagonistic, action at human metabotropic glutamate receptors (mGluRs); treatment of disorders such as epilepsy, cerebral ischemias, especially acute ischemias, spasticity etc. NOVARTIS AG (CH) 2003-12-02 US disclosed